Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Could Antioxidant Supplementation Delay Progression of Cardiovascular Disease in End-Stage Renal Disease Patients?

Author(s): Stefanos Roumeliotis, Athanasios Roumeliotis , Xenia Gorny and Peter R. Mertens*

Volume 19, Issue 1, 2021

Published on: 17 March, 2020

Page: [41 - 54] Pages: 14

DOI: 10.2174/1570161118666200317151553

Price: $65

Abstract

In end-stage renal disease patients, the leading causes of mortality are of cardiovascular (CV) origin. The underlying mechanisms are complex, given that sudden heart failure is more common than acute myocardial infarction. A contributing role of oxidative stress is postulated, which is increased even at early stages of chronic kidney disease, is gradually augmented in parallel to progression to endstage renal disease and is further accelerated by renal replacement therapy. Oxidative stress ensues when there is an imbalance between reactive pro-oxidants and physiologically occurring electron donating antioxidant defence systems. During the last decade, a close association of oxidative stress with accelerated atherosclerosis and increased risk for CV and all-cause mortality has been established. Lipid peroxidation has been identified as a trigger for endothelial dysfunction, the first step towards atherogenesis. In order to counteract the deleterious effects of free radicals and thereby ameliorate, or delay, CV disease, exogenous administration of antioxidants has been proposed. Here, we attempt to summarize existing data from studies that test antioxidants for CV protection, such as vitamins E and C, statins, omega-3 fatty acids and N-acetylcysteine.

Keywords: Antioxidants, cardiovascular disease, end-stage renal disease, haemodialysis, N-acetylcysteine, oxidative stress, peritoneal dialysis.

« Previous Next »
Graphical Abstract

[1]
Roumeliotis A, Roumeliotis S, Panagoutsos S, et al. Carotid intima-media thickness is an independent predictor of all-cause mortality and cardiovascular morbidity in patients with diabetes mellitus type 2 and chronic kidney disease. Ren Fail 2019; 41(1): 131-8.
[http://dx.doi.org/10.1080/0886022X.2019.1585372] [PMID: 30909780]
[2]
Fox CS, Matsushita K, Woodward M, et al. Chronic kidney disease prognosis consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380(9854): 1662-73.
[http://dx.doi.org/10.1016/S0140-6736(12)61350-6] [PMID: 23013602]
[3]
Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380(9854): 1649-61.
[http://dx.doi.org/10.1016/S0140-6736(12)61272-0] [PMID: 23013600]
[4]
Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States renal data system public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl 2015; 5(1): 2-7.
[http://dx.doi.org/10.1038/kisup.2015.2] [PMID: 26097778]
[5]
Cozzolino M, Galassi A, Pivari F, Ciceri P, Conte F. The cardiovascular burden in end-stage renal disease. Contrib Nephrol 2017; 191: 44-57.
[http://dx.doi.org/10.1159/000479250] [PMID: 28910790]
[6]
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382(9889): 339-52.
[http://dx.doi.org/10.1016/S0140-6736(13)60595-4] [PMID: 23727170]
[7]
Roumeliotis S, Roumeliotis A, Panagoutsos S, et al. Matrix Gla protein T-138C polymorphism is associated with carotid intima media thickness and predicts mortality in patients with diabetic nephropathy. J Diabetes Complications 2017; 31(10): 1527-32.
[http://dx.doi.org/10.1016/j.jdiacomp.2017.06.012] [PMID: 28734846]
[8]
Roumeliotis S, Dounousi E, Eleftheriadis T, Liakopoulos V. Association of the inactive circulating matrix gla protein with vitamin k intake, calcification, mortality, and cardiovascular disease: a review. Int J Mol Sci 2019; 20(3): 628.
[http://dx.doi.org/10.3390/ijms20030628] [PMID: 30717170]
[9]
Duni A, Liakopoulos V, Roumeliotis S, Peschos D, Dounousi E. Oxidative stress in the pathogenesis and evolution of chronic kidney disease: untangling Ariadne’s thread. Int J Mol Sci 2019; 20(15): 3711.
[http://dx.doi.org/10.3390/ijms20153711] [PMID: 31362427]
[10]
Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18(7): 1272-80.
[http://dx.doi.org/10.1093/ndt/gfg074] [PMID: 12808161]
[11]
Liakopoulos V, Roumeliotis S, Zarogiannis S, Eleftheriadis T, Mertens PR. Oxidative stress in hemodialysis: Causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial 2019; 32(1): 58-71.
[http://dx.doi.org/10.1111/sdi.12745] [PMID: 30288786]
[12]
Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dime-thylarginine. Am J Kidney Dis 2006; 47(1): 42-50.
[http://dx.doi.org/10.1053/j.ajkd.2005.09.029] [PMID: 16377384]
[13]
Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006; 48(5): 752-60.
[http://dx.doi.org/10.1053/j.ajkd.2006.08.015] [PMID: 17059994]
[14]
Simmons EM, Langone A, Sezer MT, et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 2005; 79(8): 914-9.
[http://dx.doi.org/10.1097/01.TP.0000157773.96534.29] [PMID: 15849543]
[15]
Descamps-Latscha B, Drüeke T, Witko-Sarsat V. Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 2001; 14(3): 193-9.
[http://dx.doi.org/10.1046/j.1525-139X.2001.00052.x] [PMID: 11422926]
[16]
Liakopoulos V, Jeron A, Shah A, Bruder D, Mertens PR, Gorny X. Hemodialysis-related changes in phenotypical features of monocytes. Sci Rep 2018; 8(1): 13964.
[http://dx.doi.org/10.1038/s41598-018-31889-2] [PMID: 30228352]
[17]
Liakopoulos V, Roumeliotis S, Gorny X, Dounousi E, Mertens PR. Oxidative stress in hemodialysis patients: a review of the literature. Oxid Med Cell Longev 2017; 20173081856
[http://dx.doi.org/10.1155/2017/3081856] [PMID: 29138677]
[18]
Susantitaphong P, Riella C, Jaber BL. Effect of ultrapure dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters: a meta-analysis. Nephrol Dial Transplant 2013; 28(2): 438-46.
[http://dx.doi.org/10.1093/ndt/gfs514] [PMID: 23291370]
[19]
Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003; 64(2): 572-8.
[http://dx.doi.org/10.1046/j.1523-1755.2003.00099.x] [PMID: 12846752]
[20]
Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65(6): 2279-89.
[http://dx.doi.org/10.1111/j.1523-1755.2004.00648.x] [PMID: 15149341]
[21]
Gritters M, Grooteman MP, Schoorl M, et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006; 21(1): 153-9.
[http://dx.doi.org/10.1093/ndt/gfi069] [PMID: 16144857]
[22]
Calò LA, Naso A, Carraro G, et al. Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrol Dial Transplant 2007; 22(5): 1413-9.
[http://dx.doi.org/10.1093/ndt/gfl783] [PMID: 17237480]
[23]
Davenport A. Effects of hemodiafiltration of inflammation and oxidative stress Springer International. Switzerland: Hemodiafiltration 2016; pp. 153-63.
[http://dx.doi.org/10.1007/978-3-319-23332-1_13]
[24]
Roumeliotis S, Eleftheriadis T, Liakopoulos V. Is oxidative stress an issue in peritoneal dialysis? Semin Dial 2019; 32(5): 463-6.
[http://dx.doi.org/10.1111/sdi.12818] [PMID: 31044475]
[25]
Liakopoulos V, Roumeliotis S, Gorny X, Eleftheriadis T, Mertens PR. Oxidative stress in patients undergoing peritoneal dialysis: a current review of the literature. Oxid Med Cell Longev 2017; 20173494867
[http://dx.doi.org/10.1155/2017/3494867] [PMID: 29750088]
[26]
Yamaji Y, Nakazato Y, Oshima N, Hayashi M, Saruta T. Oxidative stress induced by iron released from transferrin in low pH peritoneal dialysis solution. Nephrol Dial Transplant 2004; 19(10): 2592-7.
[http://dx.doi.org/10.1093/ndt/gfh278] [PMID: 15292463]
[27]
Gastaldello K, Husson C, Dondeyne JP, Vanherweghem JL, Tielemans C. Cytotoxicity of mononuclear cells as induced by peritoneal dialysis fluids: insight into mechanisms that regulate osmotic stress-related apoptosis. Perit Dial Int 2008; 28(6): 655-66.
[http://dx.doi.org/10.1177/089686080802800619] [PMID: 18981398]
[28]
Bayés B, Pastor MC, Bonal J, Foraster A, Romero R. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis--role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up. Nephrol Dial Transplant 2006; 21(4): 984-90.
[http://dx.doi.org/10.1093/ndt/gfi294] [PMID: 16326744]
[29]
Usberti M, Gerardi GM, Gazzotti RM, et al. Oxidative stress and cardiovascular disease in dialyzed patients. Nephron 2002; 91(1): 25-33.
[http://dx.doi.org/10.1159/000057601] [PMID: 12021516]
[30]
Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006; 70(1): 218-24.
[http://dx.doi.org/10.1038/sj.ki.5000330] [PMID: 16723988]
[31]
Busch M, Fleck C, Wolf G, Stein G. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology? Amino Acids 2006; 30(3): 225-32.
[http://dx.doi.org/10.1007/s00726-005-0268-8] [PMID: 16680555]
[32]
Zoccali C. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease. Blood Purif 2002; 20(5): 469-72.
[http://dx.doi.org/10.1159/000063550] [PMID: 12207095]
[33]
Zoccali C, Benedetto FA, Maas R, CREED Investigators . Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13(2): 490-6.
[PMID: 11805179]
[34]
Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62(1): 339-45.
[http://dx.doi.org/10.1046/j.1523-1755.2002.00437.x] [PMID: 12081596]
[35]
Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358(9299): 2113-7.
[http://dx.doi.org/10.1016/S0140-6736(01)07217-8] [PMID: 11784625]
[36]
Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16(8): 2449-55.
[http://dx.doi.org/10.1681/ASN.2005010076] [PMID: 15944335]
[37]
Xu H, Watanabe M, Qureshi AR, et al. Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. Perit Dial Int 2015; 35(2): 206-15.
[http://dx.doi.org/10.3747/pdi.2013.00259] [PMID: 24584621]
[38]
Drüeke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106(17): 2212-7.
[http://dx.doi.org/10.1161/01.CIR.0000035250.66458.67] [PMID: 12390950]
[39]
Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45(1): 39-47.
[http://dx.doi.org/10.1053/j.ajkd.2004.09.011] [PMID: 15696442]
[40]
Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int 2004; 66(3): 1257-65.
[http://dx.doi.org/10.1111/j.1523-1755.2004.00879.x] [PMID: 15327425]
[41]
Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003; 21(1): 3-12.
[http://dx.doi.org/10.1097/00004872-200301000-00002] [PMID: 12544424]
[42]
Kocak H, Gumuslu S, Ermis C, et al. Oxidative stress and asymmetric dimethylarginine is independently associated with carotid intima media thickness in peritoneal dialysis patients. Am J Nephrol 2008; 28(1): 91-6.
[http://dx.doi.org/10.1159/000109397] [PMID: 17914250]
[43]
Samouilidou EC, Karpouza AP, Kostopoulos V, et al. Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis. Ren Fail 2012; 34(2): 160-4.
[http://dx.doi.org/10.3109/0886022X.2011.641515] [PMID: 22172020]
[44]
Jiang J, Chen P, Chen J, et al. Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis. Atherosclerosis 2012; 224(1): 187-94.
[http://dx.doi.org/10.1016/j.atherosclerosis.2012.06.022] [PMID: 22857897]
[45]
Kayabasi H, Sit D, Atay AE, Yilmaz Z, Kadiroglu AK, Yilmaz ME. Parameters of oxidative stress and echocardiographic indexes in patients on dialysis therapy. Ren Fail 2010; 32(3): 328-34.
[http://dx.doi.org/10.3109/08860221003606299] [PMID: 20370448]
[46]
Oh HJ, Nam BY, Lee MJ, et al. Decreased circulating klotho levels in patients undergoing dialysis and relationship to oxidative stress and inflammation. Perit Dial Int 2015; 35(1): 43-51.
[http://dx.doi.org/10.3747/pdi.2013.00150] [PMID: 24497597]
[47]
Liakopoulos V, Roumeliotis S, Bozikas A, Eleftheriadis T, Dounousi E. Antioxidant supplementation in renal replacement therapy patients: is there evidence? Oxid Med Cell Longev 2019; 20199109473
[http://dx.doi.org/10.1155/2019/9109473] [PMID: 30774749]
[48]
Meagher EA. Treatment of atherosclerosis in the new millennium: is there a role for vitamin E? Prev Cardiol 2003; 6(2): 85-90.
[http://dx.doi.org/10.1111/j.1520-037X.2003.00560.x] [PMID: 12732794]
[49]
Kuhad A, Chopra K. Attenuation of diabetic nephropathy by tocotrienol: involvement of NFkB signaling pathway. Life Sci 2009; 84(9-10): 296-301.
[http://dx.doi.org/10.1016/j.lfs.2008.12.014] [PMID: 19162042]
[50]
Rashid Khan M, Ahsan H, Siddiqui S, Siddiqui WA. Tocotrienols have a nephroprotective action against lipid-induced chronic renal dysfunction in rats. Ren Fail 2015; 37(1): 136-43.
[http://dx.doi.org/10.3109/0886022X.2014.959433] [PMID: 25231142]
[51]
Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103(7): 919-25.
[http://dx.doi.org/10.1161/01.CIR.103.7.919] [PMID: 11181464]
[52]
Khor BH, Narayanan SS, Sahathevan S, et al. Efficacy of nutritional interventions on inflammatory markers in haemodialysis patients: a systematic review and limited meta-analysis. Nutrients 2018; 10(4): 397.
[http://dx.doi.org/10.3390/nu10040397] [PMID: 29570616]
[53]
Coombes JS, Fassett RG. Antioxidant therapy in hemodialysis patients: a systematic review. Kidney Int 2012; 81(3): 233-46.
[http://dx.doi.org/10.1038/ki.2011.341] [PMID: 21975860]
[54]
Islam KN, O’Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 2000; 150(1): 217-24.
[http://dx.doi.org/10.1016/S0021-9150(99)00410-4] [PMID: 10781654]
[55]
Badiou S, Cristol JP, Morena M, et al. Vitamin E supplementation increases LDL resistance to ex vivo oxidation in hemodialysis patients. Int J Vitam Nutr Res 2003; 73(4): 290-6.
[http://dx.doi.org/10.1024/0300-9831.73.4.290] [PMID: 12951902]
[56]
Baldi S, Innocenti M, Frascerra S, et al. Effects of hemodialysis and vitamin E supplementation on low-density lipoprotein oxidizability in end-stage renal failure. J Nephrol 2013; 26(3): 549-55.
[http://dx.doi.org/10.5301/jn.5000190] [PMID: 22941872]
[57]
Giray B, Kan E, Bali M, Hincal F, Basaran N. The effect of vitamin E supplementation on antioxidant enzyme activities and lipid perox-idation levels in hemodialysis patients. Clin Chim Acta 2003; 338(1-2): 91-8.
[http://dx.doi.org/10.1016/j.cccn.2003.07.020] [PMID: 14637272]
[58]
Uzum A, Toprak O, Gumustas MK, Ciftci S, Sen S. Effect of vitamin E therapy on oxidative stress and erythrocyte osmotic fragility in patients on peritoneal dialysis and hemodialysis. J Nephrol 2006; 19(6): 739-45.
[PMID: 17173246]
[59]
Boudouris G, Verginadis II, Simos YV, et al. Oxidative stress in patients treated with continuous ambulatory peritoneal dialysis (CAPD) and the significant role of vitamin C and E supplementation. Int Urol Nephrol 2013; 45(4): 1137-44.
[http://dx.doi.org/10.1007/s11255-012-0334-6] [PMID: 23212145]
[60]
Daud ZAM, Tubie B, Sheyman M, et al. Vitamin E tocotrienol supplementation improves lipid profiles in chronic hemodialysis patients. Vasc Health Risk Manag 2013; 9: 747-61.
[PMID: 24348043]
[61]
Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356(9237): 1213-8.
[http://dx.doi.org/10.1016/S0140-6736(00)02783-5] [PMID: 11072938]
[62]
Himmelfarb J, Ikizler TA, Ellis C, et al. Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial. J Am Soc Nephrol 2014; 25(3): 623-33.
[http://dx.doi.org/10.1681/ASN.2013050545] [PMID: 24371300]
[63]
Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142(1): 37-46.
[http://dx.doi.org/10.7326/0003-4819-142-1-200501040-00110] [PMID: 15537682]
[64]
Mune M, Yukawa S, Kishino M, et al. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int Suppl 1999; 71: S126-9.
[http://dx.doi.org/10.1016/S0085-2538(15)46619-0] [PMID: 10412755]
[65]
Sosa MA, Balk EM, Lau J, et al. A systematic review of the effect of the Excebrane dialyser on biomarkers of lipid peroxidation. Nephrol Dial Transplant 2006; 21(10): 2825-33.
[http://dx.doi.org/10.1093/ndt/gfl376] [PMID: 16861726]
[66]
D’Arrigo G, Baggetta R, Tripepi G, Galli F, Bolignano D. Effects of vitamin e-coated versus conventional membranes in chronic hemodialysis patients: a systematic review and meta-analysis. Blood Purif 2017; 43(1-3): 101-22.
[http://dx.doi.org/10.1159/000453444] [PMID: 27960188]
[67]
Yang SK, Xiao L, Xu B, Xu XX, Liu FY, Sun L. Effects of vitamin E-coated dialyzer on oxidative stress and inflammation status in hemodialysis patients: a systematic review and meta-analysis. Ren Fail 2014; 36(5): 722-31.
[http://dx.doi.org/10.3109/0886022X.2014.890858] [PMID: 24575826]
[68]
Jayedi A, Rashidy-Pour A, Parohan M, Zargar MS, Shab-Bidar S. Dietary and circulating vitamin C, vitamin E, β-carotene and risk of total cardiovascular mortality: a systematic review and dose-response meta-analysis of prospective observational studies. Public Health Nutr 2019; 22(10): 1872-87.
[http://dx.doi.org/10.1017/S1368980018003725] [PMID: 30630552]
[69]
Ashor AW, Brown R, Keenan PD, Willis ND, Siervo M, Mathers JC. Limited evidence for a beneficial effect of vitamin C supplementation on biomarkers of cardiovascular diseases: an umbrella review of systematic reviews and meta-analyses. Nutr Res 2019; 61: 1-12.
[http://dx.doi.org/10.1016/j.nutres.2018.08.005] [PMID: 30683434]
[70]
Deicher R, Ziai F, Bieglmayer C, Schillinger M, Hörl WH. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16(6): 1811-8.
[http://dx.doi.org/10.1681/ASN.2004100850] [PMID: 15814831]
[71]
Dashti-Khavidaki S, Talasaz AH, Tabeefar H, et al. Plasma vitamin C concentrations in patients on routine hemodialysis and its relationship to patients’ morbidity and mortality. Int J Vitam Nutr Res 2011; 81(4): 197-203.
[http://dx.doi.org/10.1024/0300-9831/a000065] [PMID: 22237767]
[72]
Cross JM, Donald AE, Nuttall SL, Deanfield JE, Woolfson RG, Macallister RJ. Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure. Kidney Int 2003; 63(4): 1433-42.
[http://dx.doi.org/10.1046/j.1523-1755.2003.00852.x] [PMID: 12631359]
[73]
Ghiadoni L, Cupisti A, Huang Y, et al. Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 2004; 17(4): 512-9.
[PMID: 15372412]
[74]
Williams MJ, Sutherland WH, McCormick MP, de Jong SA, McDonald JR, Walker RJ. Vitamin C improves endothelial dysfunction in renal allograft recipients. Nephrol Dial Transplant 2001; 16(6): 1251-5.
[http://dx.doi.org/10.1093/ndt/16.6.1251] [PMID: 11390728]
[75]
Sato M, Matsumoto Y, Morita H, Takemura H, Shimoi K, Amano I. Effects of vitamin supplementation on microcirculatory disturbance in hemodialysis patients without peripheral arterial disease. Clin Nephrol 2003; 60(1): 28-34.
[http://dx.doi.org/10.5414/CNP60028] [PMID: 12872855]
[76]
Candan F, Gültekin F, Candan F. Effect of vitamin C and zinc on osmotic fragility and lipid peroxidation in zinc-deficient haemodialysis patients. Cell Biochem Funct 2002; 20(2): 95-8.
[http://dx.doi.org/10.1002/cbf.947] [PMID: 11979503]
[77]
Ferretti G, Bacchetti T, Masciangelo S, Pallotta G. Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 2008; 41(6): 381-6.
[http://dx.doi.org/10.1016/j.clinbiochem.2007.12.011] [PMID: 18194672]
[78]
Chan D, Irish A, Croft KD, Dogra G. Effect of ascorbic acid supplementation on plasma isoprostanes in haemodialysis patients. Nephrol Dial Transplant 2006; 21(1): 234-5.
[http://dx.doi.org/10.1093/ndt/gfi154] [PMID: 16204285]
[79]
Fumeron C, Nguyen-Khoa T, Saltiel C, et al. Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant 2005; 20(9): 1874-9.
[http://dx.doi.org/10.1093/ndt/gfh928] [PMID: 15972322]
[80]
Washio K, Inagaki M, Tsuji M, et al. Oral vitamin C supplementation in hemodialysis patients and its effect on the plasma level of oxidized ascorbic acid and Cu/Zn superoxide dismutase, an oxidative stress marker. Nephron Clin Pract 2008; 109(2): c49-54.
[http://dx.doi.org/10.1159/000137628] [PMID: 18544955]
[81]
De Vriese AS, Borrey D, Mahieu E, et al. Oral vitamin C administration increases lipid peroxidation in hemodialysis patients. Nephron Clin Pract 2008; 108(1): c28-34.
[http://dx.doi.org/10.1159/000112526] [PMID: 18087169]
[82]
Eiselt J, Racek J, Opatrný K Jr, Trefil L, Stehlík P. The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C. Blood Purif 2006; 24(5-6): 531-7.
[http://dx.doi.org/10.1159/000096474] [PMID: 17077626]
[83]
Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med 2018; 378(7): 603-14.
[http://dx.doi.org/10.1056/NEJMoa1710933] [PMID: 29130810]
[84]
Witko-Sarsat V, Gausson V, Nguyen AT, et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003; 64(1): 82-91.
[http://dx.doi.org/10.1046/j.1523-1755.2003.00044.x] [PMID: 12787398]
[85]
Amore A, Formica M, Giacchino F, et al. N-Acetylcysteine in hemodialysis diabetic patients resets the activation of NF-kB in lymphomonocytes to normal values. J Nephrol 2013; 26(4): 778-86.
[http://dx.doi.org/10.5301/jn.5000167] [PMID: 23065916]
[86]
Trimarchi H, Mongitore MR, Baglioni P, et al. N-acetylcysteine reduces malondialdehyde levels in chronic hemodialysis patients--a pilot study. Clin Nephrol 2003; 59(6): 441-6.
[http://dx.doi.org/10.5414/CNP59441] [PMID: 12834176]
[87]
Thaha M. Widodo, Pranawa W, Yogiantoro M, Tomino Y. Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Clin Nephrol 2008; 69(1): 24-32.
[http://dx.doi.org/10.5414/CNP69024] [PMID: 18226399]
[88]
Giannikouris I. The effect of N-acetylcysteine on oxidative serum biomarkers of hemodialysis patients. Hippokratia 2015; 19(2): 131-5.
[PMID: 27418761]
[89]
Saddadi F, Alatab S, Pasha F, Ganji MR, Soleimanian T. The effect of treatment with N-acetylcysteine on the serum levels of C-reactive protein and interleukin-6 in patients on hemodialysis. Saudi J Kidney Dis Transpl 2014; 25(1): 66-72.
[http://dx.doi.org/10.4103/1319-2442.124489] [PMID: 24434384]
[90]
Swarnalatha G, Ram R, Neela P, Naidu MU, Dakshina Murty KV. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress. Saudi J Kidney Dis Transpl 2010; 21(5): 852-8.
[PMID: 20814119]
[91]
Hsu SP, Chiang CK, Yang SY, Chien CT. N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients. Nephron Clin Pract 2010; 116(3): c207-16.
[http://dx.doi.org/10.1159/000317201] [PMID: 20606481]
[92]
Sajwani SH, Bargman JM. Novel ways to preserve the peritoneal membrane. Adv Perit Dial 2012; 28: 37-41.
[PMID: 23311211]
[93]
Nascimento MM, Suliman ME, Silva M, et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int 2010; 30(3): 336-42.
[http://dx.doi.org/10.3747/pdi.2009.00073] [PMID: 20190028]
[94]
Purwanto B, Prasetyo DH. Effect of oral N-acetylcysteine treatment on immune system in continuous ambulatory peritoneal dialysis pa-tients. Acta Med Indones 2012; 44(2): 140-4.
[PMID: 22745145]
[95]
Sahin G, Yalcin AU, Akcar N. Effect of N-acetylcysteine on endothelial dysfunction in dialysis patients. Blood Purif 2007; 25(4): 309-15.
[http://dx.doi.org/10.1159/000106103] [PMID: 17643057]
[96]
Wittstock A, Burkert M, Zidek W, Tepel M, Scholze A. N-acetylcysteine improves arterial vascular reactivity in patients with chronic kidney disease. Nephron Clin Pract 2009; 112(3): c184-9.
[http://dx.doi.org/10.1159/000218107] [PMID: 19439989]
[97]
Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004; 109(3): 369-74.
[http://dx.doi.org/10.1161/01.CIR.0000109492.65802.AD] [PMID: 14732754]
[98]
Tsai J-P, Yang F-L, Wang C-H, et al. Effect of intravenous N-acetylcysteine on plasma total homocysteine and inflammatory cytokines during high flux hemodialysis. Tzu-Chi Med J 2010; 22(2): 90-5.
[http://dx.doi.org/10.1016/S1016-3190(10)60047-X]
[99]
Thaha M, Yogiantoro M, Tomino Y. Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homo-cysteine in patients with end-stage renal disease. Clin Drug Investig 2006; 26(4): 195-202.
[http://dx.doi.org/10.2165/00044011-200626040-00003] [PMID: 17163251]
[100]
Ivanovski O, Szumilak D, Nguyen-Khoa T, et al. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 2005; 67(6): 2288-94.
[http://dx.doi.org/10.1111/j.1523-1755.2005.00332.x] [PMID: 15882270]
[101]
Kuo KL, Hung SC, Lin YP, et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS One 2012; 7(12)e50295
[http://dx.doi.org/10.1371/journal.pone.0050295] [PMID: 23227165]
[102]
Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107(7): 992-5.
[http://dx.doi.org/10.1161/01.CIR.0000050628.11305.30] [PMID: 12600912]
[103]
Diepeveen SH, Verhoeven GW, Van Der Palen J, et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. J Intern Med 2005; 257(5): 438-45.
[http://dx.doi.org/10.1111/j.1365-2796.2005.01484.x] [PMID: 15836660]
[104]
Kishimoto N, Hayashi T, Sakuma I, et al. A hydroxymethylglutaryl coenzyme A reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis. Int J Cardiol 2010; 145(1): 21-6.
[http://dx.doi.org/10.1016/j.ijcard.2009.05.023] [PMID: 19481279]
[105]
Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2009; 8(3)CD004289
[http://dx.doi.org/10.1002/14651858.CD004289.pub4] [PMID: 19588351]
[106]
Deng J, Wu Q, Liao Y, Huo D, Yang Z. Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: a sys-tematic review and meta-analysis. Nephrology (Carlton) 2012; 17(6): 545-51.
[http://dx.doi.org/10.1111/j.1440-1797.2012.01597.x] [PMID: 22429568]
[107]
Wanner C, Tonelli M. Kidney disease: improving global outcomes lipid guideline development work group members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85(6): 1303-9.
[http://dx.doi.org/10.1038/ki.2014.31] [PMID: 24552851]
[108]
Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43(4): 589-99.
[http://dx.doi.org/10.1053/j.ajkd.2003.12.023] [PMID: 15042535]
[109]
Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22(1): 118-27.
[http://dx.doi.org/10.1093/ndt/gfl538] [PMID: 16998214]
[110]
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181-92.
[http://dx.doi.org/10.1016/S0140-6736(11)60739-3] [PMID: 21663949]
[111]
Hung AM, Booker C, Ellis CD, et al. Omega-3 fatty acids inhibit the up-regulation of endothelial chemokines in maintenance hemodialysis patients. Nephrol Dial Transplant 2015; 30(2): 266-74.
[http://dx.doi.org/10.1093/ndt/gfu283] [PMID: 25204316]
[112]
Taheri S, Keyvandarian N, Moeinzadeh F, Mortazavi M, Naini AE. The effect of omega-3 fatty acid supplementation on oxidative stress in continuous ambulatory peritoneal dialysis patients. Adv Biomed Res 2014; 3: 143.
[PMID: 25161990]
[113]
Naini AE, Asiabi RE, Keivandarian N, Moeinzadeh F. Effect of omega-3 supplementation on inflammatory parameters in patients on chronic ambulatory peritoneal dialysis. Adv Biomed Res 2015; 4: 167.
[http://dx.doi.org/10.4103/2277-9175.162544] [PMID: 26436081]
[114]
Naini AE, Keyvandarian N, Mortazavi M, Taheri S, Hosseini SM. Effect of Omega-3 fatty acids on blood pressure and serum lipids in continuous ambulatory peritoneal dialysis patients. J Res Pharm Pract 2015; 4(3): 135-41.
[http://dx.doi.org/10.4103/2279-042X.162356] [PMID: 26312252]
[115]
Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018; 7CD003177
[PMID: 30019766]
[116]
Aung T, Halsey J, Kromhout D, et al. Omega-3 Treatment Trialists’ Collaboration. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol 2018; 3(3): 225-34.
[http://dx.doi.org/10.1001/jamacardio.2017.5205] [PMID: 29387889]
[117]
Roumeliotis S, Roumeliotis A, Dounousi E, Eleftheriadis T, Liakopoulos V. Dietary antioxidant supplements and uric acid in chronic kidney disease: a review. Nutrients 2019; 11(8): 1911.
[http://dx.doi.org/10.3390/nu11081911] [PMID: 31443225]
[118]
Jun M. Antioxidants for chronic kidney disease. Nephrology (Carlton) 2013; 18(8): 576-8.
[http://dx.doi.org/10.1111/nep.12103] [PMID: 23865542]
[119]
Jun M, Venkataraman V, Razavian M, et al. Antioxidants for chronic kidney disease. Cochrane Database Syst Rev 2012; 10CD008176
[PMID: 23076940]

Rights & Permissions Print Cite
Article Metrics
17
© 2024 Bentham Science Publishers | Privacy Policy